What's on bio­phar­ma's auc­tion block? EY tracks a grow­ing ap­petite for pipeline di­vest­ment deals

Last fall the re­search arm of the Fi­nan­cial Times went out and took the in­dus­try’s pulse on deal­mak­ing. And they found that there’s been a big in­crease in ap­petite for di­vest­ments in the life sci­ences busi­ness, ac­cord­ing to the EY M&A Out­look and Fire­pow­er Re­port 2017.

Dri­ven by some new re­al­i­ties in achiev­ing drug re­im­burse­ments, the de­clin­ing for­tunes of cer­tain dis­ease sec­tors like di­a­betes as well as a new ad­min­is­tra­tion de­ter­mined to re­peal Oba­macare, some 28% of the ex­ecs they sur­veyed in the C-suite said they had busi­ness teams out beat­ing the bush­es for R&D as­sets that could be sold. That’s three times the lev­el of in­ter­est they found in 2015.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER